Drugs / Furaprevir

Trials 7 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 14 trials
Phase 1 NCT03610880 Oct 2017 → Feb 2018 Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd. Completed No outcome recorded
Phase 1 NCT03610867 Apr → Aug 2017 Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd. Completed No outcome recorded
Phase 1 NCT02108418 Apr → Jun 2014 TaiGen Biotechnology Co., Ltd. Completed No outcome recorded
Phase 1 NCT01523990 Oct 2011 → Apr 2012 chronic hepatitis C virus infection TaiGen Biotechnology Co., Ltd. Completed No outcome recorded
Phase 22 trials
Phase 2 NCT03593447 Mar 2018 → Apr 2019 chronic hepatitis C virus infection, cirrhosis of liver Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd. Completed No outcome recorded
Phase 2 NCT02340962 May 2015 → Aug 2016 chronic hepatitis C virus infection TaiGen Biotechnology Co., Ltd. Completed No outcome recorded
Phase 31 trial
Phase 3 NCT04155515 Jun 2019 → Aug 2020 chronic hepatitis C virus infection, cirrhosis of liver Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd. Completed No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 8 sources stand behind the page.

FieldValueCited text
Known as Furaprevir “TG-2349 (Furaprevir) is available as a Swedish orange capsule (size 0) for oral administration.” NCT02340962
1

NCT03610867

Known as TG-2349 ClinicalTrials.gov intervention name — accepted as the source's own label NCT01523990
5

NCT04155515

NCT03610880

NCT03593447

NCT02108418

NCT02340962

Modality Small molecule CHEMBL4297647
Route Oral “The entire content of the syringe is to be taken by mouth.” NCT01523990